AAV Vector Gene Therapy for PKP2 Mutation-Driven Cardiomyopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for effective treatments for arrhythmogenic right ventricular cardiomyopathy (ARVC) and related disorders, particularly those associated with mutations in the PKP2 gene, which affect the formation and function of desmosomes in the heart, leading to arrhythmias and increased risk of sudden death.
Innovation Solution
Gene therapy using a vector expressing Plakophilin-2 (PKP2) or a functional variant thereof, delivered via a recombinant adeno-associated virus (rAAV) vector, which includes a polynucleotide sequence encoding PKP2 linked to cardiac-specific promoters to enhance expression in heart muscle cells, thereby addressing the genetic defect underlying ARVC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy using rAAV vector expressing PKP2 is administered to treat ARVC, then PKP2 expression is significantly increased and heart function is improved, but the complexity of the treatment protocol and vector design increases
Solution Approach 1:
The gene therapy vector is segmented into distinct functional modules: the rAAV viral capsid for delivery, the ITRs for replication, the cardiac-specific promoter (MHCK7 or hTNNT2) for tissue-specific expression control, the PKP2 coding sequence for therapeutic effect, and the polyA signal for transcription termination. This modular segmentation allows each component to be optimized independently while maintaining overall system functionality.
Solution Approach 2:
The patent uses cardiac-specific promoter sequences (MHCK7 or hTNNT2) as intermediaries to bridge the gap between the viral delivery system and the therapeutic gene expression. These promoters act as mediators that ensure the PKP2 gene is expressed specifically in cardiomyocytes, enhancing therapeutic efficacy while minimizing off-target effects. The ITRs also serve as intermediaries that facilitate viral genome replication and maintenance.
2Productivity
If cardiac-specific promoters are used to enhance PKP2 expression in heart muscle cells, then expression specificity and efficacy are improved, but the difficulty of vector construction and promoter selection increases
Solution Approach 1:
The patent utilizes well-characterized cardiac-specific promoters (MHCK7 and hTNNT2) with known expression patterns and strengths. By selecting from these established promoters, the patent optimizes the parameter of expression level while maintaining manageable construction complexity. The promoters have been extensively studied and validated, providing predictable expression patterns in cardiomyocytes.
3Reliability
If gene therapy is administered early to prevent ARVC progression, then the effectiveness of treatment is improved, but the difficulty of early diagnosis and patient identification increases
Solution Approach 1:
The patent targets patients with known PKP2 mutations, using genetic testing as a feedback mechanism to identify suitable candidates before clinical symptoms manifest. This feedback approach allows for early intervention in individuals at high risk of developing ARVC, enabling treatment before significant myocardial damage occurs. The genetic marker serves as an early warning system that triggers preventive therapy.
Data Source
AI summary
Provided herein is a gene therapy for PKP2 (Plakophilin-2), e.g. using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter or a cardiac troponin T (HTNNT2) promoter. The capsid may be an AAV9 or AAVrh74 capsid or a functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the rAAV vector, and other compositions and methods.